Sarcopenia with limited mobility: An international consensus

John E. Morley, Angela Marie Abbatecola, Josep M. Argiles, Vickie Baracos, Juergen Bauer, Shalender Bhasin, Tommy Cederholm, Andrew J. Stewart Coats, Steven R. Cummings, William J. Evans, Kenneth Fearon, Luigi Ferrucci, Roger A. Fielding, Jack M. Guralnik, Tamara B. Harris, Akio Inui, Kamyar Kalantar-Zadeh, Bridget-Anne Kirwan, Giovanni Mantovani, Maurizio MuscaritoliAnne B. Newman, Filippo Rossi-Fanelli, Giuseppe M. C. Rosano, Ronenn Roubenoff, Morris Schambelan, Gerald H. Sokol, Thomas W. Storer, Bruno Vellas, Stephan von Haehling, Shing-Shing Yeh, Stefan D. Anker

Research output: Contribution to journalArticlepeer-review

809 Citations (Scopus)


A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that "Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. "Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalJournal of the American Medical Directors Association
Issue number6
Publication statusPublished - Jul 2011

Cite this